The Montreal-FH-SCORE: A new score to predict cardiovascular events in familial hypercholesterolemia

Journal of Clinical Lipidology

Volumn 11, Issue 1, 2017, Pages 80-86

  Paquette, Martine ^a   Dufour, Robert ^a,b   Baass, Alexis ^a,c  

^a CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

Age; Cardiovascular disease; Familial hypercholesterolemia; Gender; HDL C; Hypertension; Risk prediction; Smoking

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR;

ADULT; AGE; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR DISEASE ASSESSMENT; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; DYSLIPIDEMIA; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; GENDER; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; HYPERTENSION; LIPOPROTEIN BLOOD LEVEL; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONTREAL FAMILIAL HYPERCHOLESTEROLEMIA SCORE; PREDICTOR VARIABLE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SMOKING; CARDIOVASCULAR DISEASES; COMPLICATION; GENETICS; MUTATION; PROGNOSIS; RISK ASSESSMENT; YOUNG ADULT;

ADULT; CARDIOVASCULAR DISEASES; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; RISK ASSESSMENT; YOUNG ADULT;

EID: 85006166617     PISSN: 19332874     EISSN: 18764789     Source Type: Journal    
DOI: 10.1016/j.jacl.2016.10.004     Document Type: Article

References (33)

1. 1 Marais, A.D., Familial hypercholesterolaemia. Clin Biochem Rev 25:1 (2004), 49–68.
2. 2 Celermajer, D.S., Sorensen, K.E., Gooch, V.M., et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 340:8828 (1992), 1111–1115.
3. 3 Nordestgaard, B.G., Chapman, M.J., Humphries, S.E., et al., European Atherosclerosis Society Consensus Panel. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J 34:45 (2013), 3478–3490.
4. 4 Goldstein, J., Brown, M., Familial hypercholesterolemia. Scriver, C., Beaudet, A., Sly, W., (eds.) The metabolic basis of inherited diseases, 1989, Mc Graw-Hill, New York, 1215–1250.
5. 5 de Ferranti, S.D., Rodday, A.M., Mendelson, M.M., Wong, J.B., Leslie, L.K., Sheldrick, R.C., Prevalence of Familial Hypercholesterolemia in the 1999 to 2012 United States National Health and Nutrition Examination Surveys (NHANES). Circulation 133:11 (2016), 1067–1072.
6. 6 Moorjani, S., Roy, M., Gagné, C., et al. Homozygous familial hypercholesterolemia among French Canadians in Québec Province. Arteriosclerosis 9:2 (1989), 211–216.
7. 7 Innerarity, T.L., Mahley, R.W., Weisgraber, K.H., et al. Familial defective apolipoprotein B-100: a mutation of apolipoprotein B that causes hypercholesterolemia. J Lipid Res 31:8 (1990), 1337–1349.
8. 8 Abifadel, M., Varret, M., Rabès, J.P., et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 34:2 (2003), 154–156.
9. 9 Scientific Steering Committee on behalf of the Simon Broome Register Group. Mortality in treated heterozygous familial hypercholesterolaemia: Implications for clinical management. Atherosclerosis 142:1 (1999), 105–112.
10. 10 Khera, A.V., Won, H.H., Peloso, G.M., et al. Diagnostic Yield and Clinical Utility of Sequencing Familial Hypercholesterolemia Genes in Patients With Severe Hypercholesterolemia. J Am Coll Cardiol 67:22 (2016), 2578–2589.
11. 11 Sijbrands, E.J., Westendorp, R.G., Defesche, J.C., de Meier, P.H., Smelt, A.H., Kastelein, J.J., Mortality over two centuries in large pedigree with familial hypercholesterolaemia: family tree mortality study. BMJ 322:7293 (2001), 1019–1023.
12. 12 Saavedra, Y.G., Dufour, R., Davignon, J., Baass, A., PCSK9 R46L, lower LDL, and cardiovascular disease risk in familial hypercholesterolemia: a cross-sectional cohort study. Arterioscler Thromb Vasc Biol 34:12 (2014), 2700–2705.
13. 13 Saavedra, Y.G., Dufour, R., Baass, A., Familial hypercholesterolemia: PCSK9 InsLEU genetic variant and prediabetes/diabetes risk. J Clin Lipidol 9:6 (2015), 786–793.e1.
14. 14 Watts, G.F., Gidding, S., Wierzbicki, A.S., et al., International Familial Hypercholesterolemia Foundation. Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. Eur J Prev Cardiol 22:7 (2015), 849–854.
15. 15 D'Agostino, R.B. Sr., Vasan, R.S., Pencina, M.J., et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 117:6 (2008), 743–753.
16. 16 Goff, D.C. Jr., Lloyd-Jones, D.M., Bennett, G., et al., American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 129:25 Suppl 2 (2014), S49–S73.
17. 17 Stone, N.J., Robinson, J.G., Lichtenstein, A.H., et al., American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 63:25 Pt B (2014), 2889–2934.
18. 18 Conroy, R.M., Pyörälä, K., Fitzgerald, A.P., et al., SCORE project group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 24:11 (2003), 987–1003.
19. 19 Primary Panel, Genest, J., Hegele, R.A., Bergeron, J., et al. Canadian Cardiovascular Society position statement on familial hypercholesterolemia. Can J Cardiol 30:12 (2014), 1471–1481.
20. 20 de Sauvage Nolting, P.R., Defesche, J.C., Buirma, R.J., Hutten, B.A., Lansberg, P.J., Kastelein, J.J., Prevalence and significance of cardiovascular risk factors in a large cohort of patients with familial hypercholesterolaemia. J Intern Med 253:2 (2003), 161–168.
21. 21 Hopkins, P.N., Stephenson, S., Wu, L.L., Riley, W.A., Xin, Y., Hunt, S.C., Evaluation of coronary risk factors in patients with heterozygous familial hypercholesterolemia. Am J Cardiol 87:5 (2001), 547–553.
22. 22 Jansen, A.C., van Aalst-Cohen, E.S., Tanck, M.W., et al. The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients. J Intern Med 256:6 (2004), 482–490.
23. 23 Holmes, D.T., Schick, B.A., Humphries, K.H., Frohlich, J., Lipoprotein(a) is an independent risk factor for cardiovascular disease in heterozygous familial hypercholesterolemia. Clin Chem 51:11 (2005), 2067–2073.
24. 24 Allard, M.D., Saeedi, R., Yousefi, M., Frohlich, J., Risk stratification of patients with familial hypercholesterolemia in a multi-ethnic cohort. Lipids Health Dis, 13, 2014, 65.
25. 25 Gaudet, D., Vohl, M.C., Perron, P., et al. Relationships of abdominal obesity and hyperinsulinemia to angiographically assessed coronary artery disease in men with known mutations in the LDL receptor gene. Circulation 97:9 (1998), 871–877.
26. 26 Ademi, Z., Watts, G.F., Juniper, A., Liew, D., A systematic review of economic evaluations of the detection and treatment of familial hypercholesterolemia. Int J Cardiol 167:6 (2013), 2391–2396.
27. 27 Committee NH and LI (U. S) LRCPLM. Manual of Laboratory Operations: Lipid and Lipoprotein Analysis, Volume 1, 1974, National Heart and Lung Institute, National Institutes of Health, New York.
28. 28 DeLong, E.R., DeLong, D.M., Clarke-Pearson, D.L., Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44:3 (1988), 837–845.
29. 29 Pandya, A., Weinstein, M.C., Gaziano, T.A., A comparative assessment of non-laboratory-based versus commonly used laboratory-based cardiovascular disease risk scores in the NHANES III population. PLoS One, 6(5), 2011, e20416.
30. 30 Hellerstein, M., Turner, S., Reverse cholesterol transport fluxes. Curr Opin Lipidol 25:1 (2014), 40–47.
31. 31 Besseling, J., Kastelein, J.J., Defesche, J.C., Hutten, B.A., Hovingh, G.K., Association between familial hypercholesterolemia and prevalence of type 2 diabetes mellitus. JAMA 313:10 (2015), 1029–1036.
32. 32 Yusuf, S., Hawken, S., Ounpuu, S., et al., INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364:9438 (2004), 937–952.
33. 33 Braamskamp, M.J., Hutten, B.A., Wiegman, A., Early initiation of statin treatment in children with familial hypercholesterolaemia. Curr Opin Lipidol 26:3 (2015), 236–239.